Liquidia Corp LQDA
Liquidia Corp (Nasdaq: LQDA) is a respiratory drug developer. Its lead program, L606 (liposomal treprostinil, inhaled via next-generation nebulizer), is in Phase 3 for pulmonary hypertension associated with interstitial lung disease (PH-ILD); also PAH (open-label).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| YUTREPIA (treprostinil inhalation powder) | PAH and PH-ILD (approved May 2025); planned studies in PH-COPD, IPF, PPF, SSc-RP | device-combination | Approved |
| L606 pivotal study | PH-ILD | device-combination | Phase 3 |
| L606 open-label study (US) | PAH and PH-ILD | device-combination | Phase 2 |
| YUTREPIA new-indication studies | PH-COPD, IPF, PPF, SSc-RP | device-combination | Pre-clinical |
Recent results and decisions
- Oct 14, 2026n/a Liquidia will continue studies to explore YUTREPIA for systemic sclerosis-associated Raynaud's phenomenon (SSc-RP) where no approved options exist.
We will continue to build on our market position through new studies to explore novel treatments for conditions like systemic sclerosis-associated Raynaud's phenomenon (SSc-RP).
Filing - Oct 14, 2026n/a Liquidia will continue pivotal studies of L606 to support PAH indication.
We will continue to build on our market position through pivotal studies of L606 to support PAH and PH-ILD indications.
Filing - Oct 14, 2026n/a Liquidia continues pivotal studies of L606 to support PAH indication.
And simultaneously, we will continue to build on our market position through post-marketing studies of YUTREPIA, pivotal studies of L606 to support PAH and PH-ILD indications, and new studies to explore novel treatments for conditions like systemic sclerosis-associated Raynaud's phenomenon (SSc-RP)
Filing
7 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.